Results 191 to 200 of about 6,266 (218)

Neuropsychiatric phenotypes of anti-NMDAR encephalitis: a prospective study

Psychological Medicine, 2022
AbstractBackgroundPatients with anti-N-methyl-d-aspartate (NMDA) receptor encephalitis (ANMDARE) show a wide range of behavioral abnormalities and are often mistaken for primary psychiatric presentations. We aimed to determine the behavioral hallmarks of ANMDARE with the use of systematic neuropsychiatric and cognitive assessments.MethodsA prospective ...
M. Espinola-Nadurille, M. Restrepo-Martínez, L. Bayliss, E. Flores-Montes, V. Rivas-Alonso, S. Vargas-Cañas, L. Hernández, I. Martínez-Juarez, A. Gonzalez-Aguilar, R. Solis-Vivanco, G. L. Fricchione, J. Flores-Rivera, J. Ramirez-Bermudez   +12 more
openaire   +2 more sources

Forecasting outcomes in anti-NMDAR encephalitis

Neurology, 2019
“It's dangerous to make forecasts, especially about the future.” Mark Twain's words hold true in many situations in medicine, particularly in critical illnesses that carry both risk of death and the chance of full recovery, exemplified by autoimmune encephalitis.
Rüegg S, Yeh EA, Honnorat J
openaire   +3 more sources

Extreme delta brush in a patient with anti‐NMDAR encephalitis

Epileptic Disorders, 2013
ABSTRACT Anti‐N‐methyl‐D‐aspartate receptor encephalitis is a severe, potentially treatable, disorder and prognosis depends on early recognition and prompt immunotherapy. We report a case of anti‐N‐methyl‐D‐aspartate receptor encephalitis with atypical age and gender, and a characteristic electroencephalographic pattern that supported
Daniela, Di Capua, Sara, García-Ptacek, Maria Eugenia, García-García, Belen, Abarrategui, Jesús, Porta-Etessam, Irene, García-Morales   +5 more
openaire   +2 more sources

Anti-NMDAR encephalitis and MOGAD – Clinical and treatment insights

Journal of Clinical Neuroscience
This letter responds to Yan et al.'s study on anti-NMDAR encephalitis combined with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), highlighting its valuable findings on clinical features, MRI lesion diversity, high relapse rates, and rituximab's efficacy in reducing recurrence.
Areeb, Fatima, Maryam, Adnan, Muhammad Irtaza, Hussain Bakhtiari   +2 more
openaire   +2 more sources

Diagnosis of pediatric anti-NMDAR encephalitis at the onset: A clinical challenge

European Journal of Paediatric Neurology, 2021
Laura Papetti, L Fusco, Federico Vigevano   +2 more
exaly  

Anti-NMDAR Encephalitis

2022
openaire   +1 more source

Anti‐N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis is associated with IRF7, BANK1 and TBX21 polymorphisms in two populations

European Journal of Neurology, 2021
Yaqing Shu, Honghao Wang, Zhengqi Lu
exaly  

Benzoate treatment for adolescent anti-NMDAR encephalitis

Schizophrenia Research, 2020
Ruu-Fen, Tzang, Yue-Cune, Chang, Hsien-Yuan, Lane   +2 more
openaire   +2 more sources

Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis

Autoimmunity Reviews, 2022
Nabil Seery, Helmut Butzkueven, Terence J O'Brien   +2 more
exaly  

The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity

Multiple Sclerosis and Related Disorders, 2021
Yu Wu, Xiaoli Cao, Wen Huang
exaly